PRAC investigating reports of Guillain-Barre syndrome with AstraZeneca’s Covid-19 vaccine

Guillain-Barre syndrome was identified during the marketing authorisation process as a possible adverse event requiring specific safety monitoring activities, therefore PRAC has requested the marketing authorisation holder to provide further detailed data.

Source:

European Medicines Agency